Zobrazeno 1 - 4
of 4
pro vyhledávání: '"La Kesla R. Iles"'
Autor:
La Kesla R. Iles, Samantha Tran, Hailing Yang, Ezzeddine Elmir, Janice M. Santiago-O'Farrill, Robert R. Langley, Philip Rask, Alicia M. Blessing, Weiqun Mao, Jing Ning, Lakshmi Reddy Bollu, Lan Pang, Geoffrey Bartholomeusz, Zhen Lu, Robert C. Bast, Daewoo Pak
Publikováno v:
Cancer. 126:3579-3592
Background Poor outcomes for patients with ovarian cancer relate to dormant, drug-resistant cancer cells that survive after primary surgery and chemotherapy. Ovarian cancer (OvCa) cells persist in poorly vascularized scars on the peritoneal surface a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0852daf55fc9853f939f80576fc19d1e
https://doi.org/10.1002/cncr.32985
https://doi.org/10.1002/cncr.32985
Autor:
Michael J. Keating, Aloke Sarkar, Gorkem Kismali, La Kesla R. Iles, Maria Teresa Sabrina Bertilaccio, Burcu Aslan, Varsha Gandhi, William G. Wierda, Xue Yi, Mary Ayres, James P. Long
Publikováno v:
Clin Cancer Res
Purpose: Survival of CLL cells due to the presence of Bcl-2 and Mcl-1 has been established. Direct inhibition of Bcl-2 by venetoclax and indirect targeting of Mcl-1 with transcription inhibitors have been successful approaches for CLL. AMG-176 is a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35fa7e1ddaa496267b3781343345bb34
https://aperta.ulakbim.gov.tr/record/11619
https://aperta.ulakbim.gov.tr/record/11619
Autor:
La Kesla R. Iles, Steven W. Millward, Helen Piwnica-Worms, Geoffrey Bartholomeusz, Yongying Jiang, Ahmed Ashour Ahmed, Hailing Yang, Weiqun Mao, Xiao Feng Le, Jinhua Zhou, Nicholas B. Jennings, Sabrina Jeter-Jones, Argentina Ornelas, Lan Pang, Abena B. Redwood, Niki M. Zacharias, Anil K. Sood, Zhang Shu, Zhen Lu, Cristian Rodriguez-Aguayo, Robert C. Bast, Gabriel Lopez-Berestein
Publikováno v:
Clinical Cancer Research. 25(18)
Purpose: Paclitaxel is an integral component of primary therapy for breast and epithelial ovarian cancers, but less than half of these cancers respond to the drug. Enhancing the response to primary therapy with paclitaxel could improve outcomes for w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d5676645a970c9a7de9967a4272b45
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid:
Autor:
Bedrich L. Eckhardt, Maria Gagliardi, Kurt W. Evans, Chang Gong Liu, La Kesla R. Iles, Funda Meric-Bernstam, Cristina Ivan, Xiuping Liu, Naoto T. Ueno, Geoffrey Bartholomeusz, Arvind Rao, Glauco R. Souza
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0195932 (2018)
PLoS ONE
PLoS ONE
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb43e96bd33ab654522ebad69d7419e
http://europepmc.org/articles/PMC5955489?pdf=render
http://europepmc.org/articles/PMC5955489?pdf=render